BE treatment improved glucose metabolism in both wild-type and db/db mice, which seems to be related to the activation of the FXR in the liver because treatment of db/db mice with the FXR agonist GW4064 decreased hyperglycemia by suppressing the expression of PEPCK and G6Pase (Zhang et al., 2006). Here, G6PC1 is linked to Hyperglycemia.